




Bu Dou
布斗科技



CHINA-EUROPE PHARMA OUTSOURCING & PARTNERSHIP CONGRESS AND DRUG DEVELOPMENT SUMMIT

25th - 27th
OCTOBER
2018



Su Zhou - CHINA

INVITATION

The global pharmaceutical industry is currently experiencing dynamic changes. Due to the high pressure of containing fixed costs, all drug companies are reducing their internal capacities in R&D and manufacturing, in the meantime, exploring the outsourcing approach. Pharmaceutical companies, big and small, now rely heavily on outsourcing their projects to service providers more than ever in order to solving their everchanging challenges, fulfil their tasks and improve operation efficiency and productivity. Thus it is crucial to create partnership opportunities to serve their collective needs.

The three-day China-Europe Pharma Outsourcing & Partnership Congress will provide a unique platform for the industry stakeholders to interact, discuss and networking with top tier pharmaceutical and biotechnology company executives as well as regional and international service providers, to discuss and share their outsourcing and partnership strategies, challenges and opportunities.

Pharma Outsourcing & Partnership Congress

Roundtable Discussions (One/Many to Many)

These interactive and informal discussion groups are the hallmark of the meeting. Small exclusive groups of leaders who face shared challenges and strategic priorities are brought together in 60-minute sessions that enable participants to share ideas and lessons learned. Facilitated by experienced professionals, these sessions provide a valuable dialogue with peers on current challenges and issues. Each discussion group has limited number of participants which ensures each delegate is given ample opportunity to raise questions and contribute to the discussion.

One-to-One Meetings

The most effective and efficient way to assess potential partners at a strategic level. Compare and update your knowledge of the industry in 40-minute informative and relaxed business meetings with solution providers of your choice.

Personalised Agenda

Each delegate receives a personalised agenda combining industry-leading keynote presentations, topics of roundtable discussions, networking and business meetings. You only attend sessions and meetings that fit your challenges and interests, ensuring your time out of the office is focused and well-utilised.

Online Community

Our online community (www.cbmda.org), enables the roundtable discussion to be prolonged and shared globally in a competitive environment. We keep the leaders connected in our user friendly and interactive platform.

Participants

Europe/USA: Top 20 Pharmaceutical companies EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads and Biotech CXOs.

China: Departments Heads, Business Development Directors, CXOs, Global Partnership Directors.



DRUG DEVELOPMENT SUMMIT

Bioinformatics and Drug Discovery

The European Union (EU) is a prevalent hub for advanced research in Bioinformatics. The Global Bioinformatics Market is estimated to gain USD 4,285.1 million by 2020 growing at a CAGR of 21.1%. The presence of increasing market appeal for database management, and demand for related sequence, structural and phylogenetic analysis tools and software is the dominant factor accounting for this large share in Bioinformatics to catalogue strong progress in the coming years.

Medicinal Chemistry

Unlike other medicinal chemistry events, the strategy meeting is exclusive to C-level executives and you can be rest assured that you only meet primary decision makers of top and emerging pharma, biotech and research organisations. Our executive roundtable discussions allow in-depth conversations about medicinal chemistry topics and trends like molecular pharmacology, drug discovery, biochemistry and more. Compared to regular medicinal chemistry summits, each delegate gets the chance to raise relevant questions or contribute innovative ideas to the exchange.

Manufacture and Supply Chain

Another key feature that makes us different from other pharma manufacturing conferences is our pre-qualified one-to-one meetings. With our extensive network of manufacturing experts in Europe and around the world, you can count on meeting someone who can help you strategise your business goals. Need help with implementing continuous manufacturing or looking for potential partners in Europe? Let us know so we can schedule your one-to-one meeting with the decision makers.



AGENDA 25th October – 27th October 2018

Wednesday 24th OCTOBER 2018

14:00-18:00 **Registration, Exhibition Setup**

Thursday 25th OCTOBER 2018

9:00-9:30 **Registration and Welcome Address**

9:30-12:30

**Externalization of Drug Discovery
in China**

Executive Director of Lilly
Oncology Research
China/Asia
Eli Lilly

**How Data-Driven Methodologies can
Improve Biomarker Development?**

Assistant Head & Assistant
Professor; Department of
Biomedical Sciences
**City University of
Hong Kong**

**Impurity Evaluation in the Process of
Drug Development**

Director, Chemical &
Computational Toxicology
Teva

**Data Mining of Big Cancer "omic"
Data: Maximizing the Chance for
Drug Discovery**

Associate Professor and Deputy
Chair, Department of
Bioinformatics and Computational
Biology. Associate Professor
Department of Systems Biology
MD Anderson Cancer Center

AI Chemogenomics Drug Discovery

Associate Dean for Research
Innovation and Professor of
Pharmaceutical Sciences,
School of Pharmacy. Director
of CCGS and CDAR Centers
University of Pittsburgh

AGENDA 25th October – 27th October 2018

Thursday 25th OCTOBER 2018

12:30–13:30 **Lunch**

13:30–17:30 **Bioinformatics in Drug Discovery
and Translation –
Insights from Patient Profiling**

Director,
Computational Biology
Boehringer Ingelheim

**From Omics Data to Cancer Treatment
– The Bioinformatics Dimension**

Head, Quantitative Biology
Center (QBiC), Eberhard Karls
Universität Tübingen
**Quantitative Biology
Center (QBiC)**

**Expanding Medicinal Chemistry Space:
The Unharnessed Potential of Protein-
Drug Conjugates, Chemically-Modified
Peptides, and Other Molecular Hybrids**

Global Head of External
Science & Drug Discovery
Global Discovery Chemistry
Novartis

**How Platform-Based Solutions for
Data Capture can Streamline R&D
Workflows?**

Chief Scientific Officer
Scilligence Corporation

**The Institute of Cancer Therapeutics:
An Integrated Oncology Drug
Discovery Pipeline – Current Projects
and Partnering Opportunities**

Director, The Institute of Cancer
Therapeutics; Director of Research,
School of Pharmacy and Medical
Sciences; Head of Ethical Tissue
**The Institute of Cancer
Therapeutics**

AGENDA 25th October – 27th October 2018

Friday 26th OCTOBER 2018

Roundtable

1-2-1 Meetings

8:30 – 9:30

Interplay between data management, analysis and visualisation of complex data to drive decision making

8:30 – 9:10

9:30 – 10:30

How to maximise project success through communications and transparent engagements

9:10 – 9:50

9:50 – 10:30

10:30 – 10:45

Tea Break

10:45 – 11:45

What are the key requirements to make fragment based drug discovery a viable and competitive tool in the drug discovery process for novel targets?

10:45 – 11: 25

11:45 – 12:45

What risk-mitigating tactics should be implemented in a GxP-outsourced partnership?

11:25 – 12:05

12:05 – 12:45

12:45 – 13:45

Lunch

Four roundtables will be facilitated by European Delegates selected Chinese industry suppliers. Minimum 5 selection to qualify.

AGENDA 25th October – 27th October 2018

Friday 26th OCTOBER 2018

Roundtable

1-2-1 Meetings

13:45 – 14:45

**Open innovation and partnerships
for an improved lead generation**

13:45 – 14:25

14:45 – 15:45

**Modelling and informatics support for
safety and metabolism studies in early
drug discovery projects**

14:25 – 15:05

15:05 – 15:45

15:45 – 16:00

Tea Break

16:00 – 17:00

**New chemical biology technologies for
target identification and highthroughput
screening: Chemical Glycobiology
and beyond**

16:00 – 16:40

17:00 – 18:00

**Ensuring a Strong Quality and
Compliance Focus with CMOs,
Partners, and Suppliers**

16:40 – 17:20

17:20 – 18:00

18:00 – 19:00


CANAPÉ & DRINKS RECEPTION

Four roundtables will be facilitated by European Delegates selected Chinese industry suppliers. Minimum 5 selection to qualify.

AGENDA 25th October – 27th October 2018

Saturday 27th OCTOBER 2018


9:00-22:00 ONE DAY CONTINUE NETWORKING TOUR – SU ZHOU, CHINA



KEYNOTE DELEGATES – EUROPE

Bioinformatics and Drug Discovery

1. Han Liang



Associate Professor and Deputy Chair, Department of Bioinformatics and Computational Biology;

**Associate Professor Department of Systems Biology
MD Anderson Cancer Center**

Dr. Liang obtained his B.S. from Peking University in 2001, received his Ph.D. from Princeton University in 2006, followed by a postdoctoral training in computational genomics at the University of Chicago. In 2009, Dr. Liang joined the Department of Bioinformatics and Computational Biology at the University of Texas MD Anderson Cancer Center as Assistant Professor. Currently, he is a tenured Full Professor and Deputy Department Chair. Since his group was established at MD Anderson, he has published >100 papers including lead corresponding-author papers in Cell, Cancer Cell, Nature Methods, Nature Biotechnology, and Nature Genetics.

2. Lidia Cappellina



Head of R&D Outsourcing Management

Chiesi Farmaceutici

Lidia is the Head of R&D Outsourcing Management for Chiesi Group. She has 25 years' experience in the pharmaceutical industry, started in 1992 in GSK Italy where she covered the role of Head of Licensing and License Management Department and subsequently she became the Head of Procurement. She moved in Astra Zeneca Italy in 2003 with the role of Strategic Business Development & Planning Director, and joined Chiesi in 2009.

3. Bing-Yan Zhu



Sr. Scientist and Principal Outsourcing Manager

Genentech

Dr. Bing-Yan Zhu is a Sr. Scientist and Principal Outsourcing Manager in the Department of Discovery Chemistry at Genentech. His current primary responsibilities are working with external CROs and internal medicinal chemistry teams to help drive small molecule drug discovery programs at Genentech. Dr. Bing-Yan Zhu is one of inventors for factor Xa inhibitor, Betrixaban which was recently approved by US FDA for the prophylaxis of venous thromboembolism (VTE). Prior to joining Genentech in 2004, Dr. Bing-Yan Zhu worked at several biotech companies including Quark Pharmaceuticals, COR Therapeutics and Biochem Pharma. Dr. Bing-Yan Zhu received his PhD degree in Organic Chemistry from the University of Alberta, Canada and his Bachelor degree in Organic Chemistry from Lanzhou University, China.

KEYNOTE DELEGATES – EUROPE

Bioinformatics and Drug Discovery

4. Sven Nahnsen



Managing Director

Quantitative Biology Center (QBiC)
Eberhard Karls Universität Tübingen

Dr. Nahnsen studied Biomathematics and Biotechnology at the Universities Greifswald (Germany), Strasbourg (France) and Cambridge (UK). He received his PhD in Computer Science from the University of Tübingen in 2010. He developed software solutions, as well as mathematical approaches for the analysis of modern high-throughput data. In 2012 he accepted the position as the head of the newly established Quantitative Biology Center (QBiC) in Tübingen. Together with his team he developed automated solutions for data and project management for clinical studies as well as bioinformatics methods for the integration of multi-scale omics data.

5. Xin Wang



Assistant Head & Assistant Professor Department of Biomedical Sciences

City University of Hong Kong

Xin Wang obtained his PhD at the University of Cambridge Department of Oncology and Cancer Research UK Cambridge Institute in 2013, where he identified molecularly distinct colon cancer subtypes using an unsupervised classification approach. From 2013 to 2015, He completed his postdoc training at Harvard Medical School Department of Biomedical Informatics, where he applied advanced techniques in next-generation sequencing data analysis to study the role of BRD4-NUT fusion gene in NUT midline carcinoma and characterized LRF as an independent repressive transcription factor of fetal hemoglobin.

6. James Weatherall Executive Director, Head of the Advanced Analytics Centre



Astrazeneca

James Weatherall is the Head of the Advanced Analytics Centre (AAC) at AstraZeneca, a department of approximately 30 clinical data scientists covering advanced statistics, scientific computing and biomedical & health informatics. The mission of the AAC is to transform drug development decision making through applied data science. A particle physicist by training, James spent time as an academic researcher, before becoming a scientific software engineer consulting across a range of different industries, including the life sciences.

KEYNOTE DELEGATES – EUROPE

Medicinal Chemistry

1. Raphael Nudelman **Director, Chemical & Computational Toxicology**



Teva

Raphael completed his Ph.D. in organic chemistry from the Weizmann Institute of Science in Israel, followed by postdoctoral positions in the US Air Force Research Lab in Aberdeen Proving Ground, Maryland USA and in Duke University Medical Center, North Carolina USA. He joined Teva Pharmaceutical Industries' Medicinal Chemistry department in 2003 and in 2010 he established the Chemical & Computational Toxicology group which he currently heads. Raphael is a member of the American Chemical Society (ACS), the American Association of Pharmaceutical Scientists (AAPS), and of the Israel Chemical Society (ICS). From 2011 to 2016, Raphael was the President of the Medicinal Chemistry Section of the Israel Chemical Society, and was as a Council member of the European Federation of Medicinal Chemistry (EFMC). He is a member of the Advisory Editorial Boards of Elsevier's journal Drug Discovery Today: Technologies, and of Trends in Medicine and Health (TMH).

2. Bayard Huck



Vice President, Global Head of Medicinal Chemistry, Merck Group

Bayard Huck is currently the Global Head of Medicinal Chemistry at Merck Biopharma (subsidiary of Merck KGaA). Bayard received his Ph.D. in Organic Chemistry from the University of Wisconsin – Madison. His medicinal chemistry experience ranges from driving multiple small molecule programs from concept to clinic, to leading multiple programs to clinical proof of concept. Currently, as Global Head of Medicinal Chemistry, Bayard oversees the medicinal chemistry efforts at Merck Biopharma in support of Immunology, Immuno- Oncology, and Oncology therapeutic areas.

3. Richard Soll



Senior Vice President, International Discovery Service Unit WuXi AppTec

Richard Soll leads the US and European discovery synthetic- and medicinal-chemistry global collaborations at WuXi that aim to provide expertise and innovative solutions for small molecule drug R&D across biopharma and life science industries. Dr. Soll's contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy elbasvir, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs. Dr. Soll has co-authored more than 100 patents and papers. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry.

KEYNOTE DELEGATES – EUROPE

Medicinal Chemistry

4. Matthew Fyfe



Director, Medicinal Chemistry

TopiVert Pharma

Matthew joined London-based biotech TopiVert at its inception to spearhead its medicinal chemistry, CMC and intellectual property activities. He has 18 years of experience as a medicinal chemist and drug discoverer, having formerly held the position of Director of Drug Discovery at Oryzon in Barcelona and Director of Medicinal Chemistry at Prosidion in Oxford. is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer reviewed publications and an inventor on over 70 patents

5. Sean Xie



Associate Dean for Research Innovation

Professor of Pharmaceutical Sciences, School of Pharmacy.

Director of CCGS and CDAR Centers

University of Pittsburgh

Xiang-Qun (Sean) Xie, MD, PhD, EMBA is an Associate Dean for Research Innovation at School of Pharmacy and a tenured Professor of Pharmaceutical Sciences/Drug Discovery Institute, and a PI of Innovation Discovery Laboratory (IDLab) of the integrated AI Computing, Bioassay and MedChem chemogenomics screening drug discovery platform at University of Pittsburgh. He is a Charter Member of Science Board to the US FDA and the Founding Director/PI of NIH-funded National Center of Excellence for Computational Drug Abuse Research. He is an Editorial Advisory Board member for AAPS Journal and American Journal of Molecular Biology. He is Founder/CSO and Chair of the Board of a Pitt-spin off startup company, awarded by NIH SBIR Fast-Track FDA IND-enabling studies of new anti-tumor drug translational research. He was a recipient of 2014 AAPS Award for Outstanding Research Achievements, and was nominated for UPit Chancellor's Outstanding Research Award in 2018.

6. Steven Hu



Senior Director & Head of CMC in Roche Pharm Research and Development (pRED)


Roche

Steven Hu currently is the Senior Director & Head of CMC in Roche Pharm Research and Development (pRED) Shanghai, being responsible for process research and synthesis, analytical, preformulation and formulation development to support Roche China portfolio. Before joining Roche, Steven was the Director of New Product Development (NPD) of GSK China R&D, overseeing the whole drug product development life cycle from formulation development and optimization, process development and scale-up to technology transfer to commercial manufacturing.

KEYNOTE DELEGATES – EUROPE

Manufacture and Supply Chain

1. Xiang S Ye



Executive Director of Oncology Research China/Asia

Eli Lilly

Dr. Xiang S Ye is the executive director of Eli Lilly Oncology Discovery China/Asia. Dr. Ye joined Eli Lilly in early 1998. At Lilly, Dr. Ye led discovery research efforts for novel cancer drugs targeting cancer cell cycle and signaling and delivered 8 clinical candidates, including abemaciclib, a CDK4/6 inhibitor, designated as a breakthrough medicine, and approved by FDA in 2017. In 2008, Dr. Ye has published more than 60 scientific papers and book chapters. Dr. Ye was relocated to Shanghai in 2011 to lead Lilly Oncology Discovery China/Asia and delivered the first clinical candidate in early 2014 from

China discovery research. In his current role, Dr. Ye also supervised postdoctoral scientists, served as corporate supervisor at Shanghai Science and Technology University, and has leadership roles in several pre-competitive consortia programs and academic collaborations to promote cancer research and drug development in China/Asia.

2. Roman Necina



Vice President, Process Development and Technical Services

Shire

Roman Necina has been with Baxter since 2011 and is currently the Vice President of Process Science & Technical Operations at Baxalta and he also holds the title of General Manager Baxter Innovations. Roman has extensive experience in the pharma sector over a span of 25 years and has accomplished many achievements including Process Development, Tech Transfer, Scale-up and GMP production of drug substances and drug products for more than 40 different biologicals. His pharmaceutical career started in 1999 with Boehringer Ingelheim as a Protein

Chemist where he rose to become Vice President Biopharmaceutical Production & Process Science before moving to Intercell in several senior management roles until 2011 after which he joined Baxter.

3. Richard Farquharson Executive Director, Distribution, Global Operations



AstraZeneca

Richard is Head of Distribution & Logistics within the EMEA region for all AstraZeneca pharmaceutical products, this includes freight forwarding, warehousing activities and onward transportation to point of sale. This is delivered through a combination of in-house DCs and outsourced LSPs. Richard chairs the AstraZeneca Global Distribution Network, which is responsible for the AZ distribution & logistics strategy, sets consistent standards and drives supply chain improvements working with R&D, Global Supply Chain & Commercial functions.

KEYNOTE DELEGATES – EUROPE

Manufacture and Supply Chain

4. Thibaud Stoll



Senior Vice President, Head Global Biotech Manufacturing & Development **Merck**

Thibaud leads a global network of sites in charge of the technical development and manufacturing of biopharmaceuticals within the Healthcare division of the Merck Group. Prior to working at Merck, Thibaud held various positions of growing responsibility in biotech, pharma and vaccine companies, in both technical development and manufacturing. He has been Vice President for Belgium Operations with GSK Vaccines and Head of Global Biopharmaceutical Operations at Novartis & Sandoz in Switzerland, in charge of clinical and commercial manufacturing of biopharmaceuticals and biosimilars. At Novartis, he has pioneered the implementation of LEAN to biomanufacturing. He started his career at Genentech, in California.

5. Valdas Jurkauskas Senior Director of Pharmaceutical Development, Manufacturing & Quality **Corbus Pharmaceuticals**



Dr. Jurkauskas' expertise is in process development, drug substance and drug product manufacturing, commercial process validation, and regulatory filings. Prior to joining Corbus, Dr. Jurkauskas led Technical Operations at STA Pharmaceuticals Co., Ltd., a WuXi AppTec and Active Pharmaceutical Ingredient Process Development at Cubist Pharmaceuticals, which was acquired by Merck & Co., Inc.. He was a member of Chemical Development at Vertex Pharmaceuticals. Dr. Jurkauskas earned his PhD degree in Organic Chemistry at the Massachusetts Institute of Technology under the guidance of Professor Stephen L. Buchwald.

6. Luca Russo



Vice President, Head of Clinical Supply Chain **Johnson & Johnson**

Luca Russo currently serves as Vice President and Head of Clinical Supply Chain at Janssen. Mr. Russo is globally accountable for the source, plan, make, delivery of the Janssen R&D supply chain, and further responsible for the support of clinical supplies – scale up from early to late stage development, as well as new product launches. Previously, Mr. Russo served as General Manager of Janssen's site in Latina, Italy. Mr. Russo has 18 years of experience in the operations and supply chain management of 2 major multinational USA corporations in consumer and pharma business. Asia: the challenges and the great potential Innovation and R&D for China.

PAST PARTICIPANTS LIST –EUROPE

Bioinformatics and Drug Discovery

COMPANY	JOB TITLE
AFFIRIS AG	Head of Scientific IT Department
Astex Pharmaceuticals	Associate Director
AstraZeneca	Head, Advanced Analytics Centre
AstraZeneca	Associate Principal Informatics Scientist
AstraZeneca	Global Director, Biomedical Informatics
Bayer	Team Lead Crop Efficiency Biochemistry
Bayer	Head Genomics Biomarker Statistics
Bayer CropScience	Group leader X-Functional Data Science
Bayer CropScience	Group Leader
Bayer Pharma AG	Head of Research and Development IT
Bayer Pharma AG	Business Partner Clinical Sciences Biomarker
Bayer Vegetable Seeds	Global Head Technology Development
BioMérieux	Corporate VP, CTO and Innovation
Biozentrum, University of Basel	Head, Research IT
Boehringer Ingelheim Pharma GmbH & Co KG	Head of IT Translational Science & Epidemiology
Boehringer Ingelheim Pharma GmbH & Co. KG	Principal Scientist Computational Biology
Brunel University London	Professor, Head of Department of Life Sciences
Cancer Research UK	Head of Scientific Computing
CNG	Head of Bioinformatics
CRUK	Head of Scientific Computing
e-Therapeutics	Head of Discovery Informatics
Eli Lilly	Director IT – Biology systems and Neuroscience
EMBL	Head of EMBL Genomics CF
F. Hoffmann–La Roche AG	Head IDW Platform Services
GalxoSmithKline (GSK)	Head Computational Biology
GlaxoSmithKline (GSK)	Head, Respiratory Data Sciences Group
GlaxoSmithKline (GSK)	Head Translational Research
Janssen	Associate Scientific Director Discovery Data Sciences
Johnson & Johnson	Senior IT Director
Johnson & Johnson	Director integrated data & analytics (DnA)
Johnson & Johnson	Translational Informatics and External Innovation
MedImmune	Principle Bioinformatics Scientist
MedImmune	Director of Research Bioinformatics
Novartis	Global Head of Preclinical Safety Informatics
F. Hoffmann–La Roche AG	Head Small Molecule Discovery Workflows
F. Hoffmann–La Roche AG	Head of Global BI Solution Centre
F. Hoffmann–La Roche AG	IT site head
F. Hoffmann–La Roche AG	Global Head of Knowledge Management
Sanofi–Aventis	Head of IT Paris Center–Leader of Data Access,
Sanofi–Aventis	Visualization, Analytics & Scientific Computing
Sanofi–Aventis	ITS R&D Domain Leader – Analytics
Sanofi–Aventis	Domain Leader & Head of Competency Center

PAST PARTICIPANTS LIST –EUROPE

Medicinal Chemistry

COMPANY	JOB TITLE
ABAC Therapeutics	CEO
Abbvie	Director Immunology Chemistry
Antikor Biopharma Ltd	Director Medicinal Chemistry
Astex Pharmaceuticals	VP of Discovery Technology
Astrazeneca	Global Head Research Outsourcing
AstraZeneca	Director Medicinal Chemistry iMed CVMD pÅ
AstraZeneca	Associate Director Medicinal Chemistry
Boehringer Ingelheim	Director Medicinal Chemistry
Boehringer Ingelheim	Senior Vice President Research
Boehringer Ingelheim RCV GmbH & Co KG	Research Laboratory Head
Cancer Research Technology Discovery Laboratories	Senior Group Leader and Cambridge Site Lead
Domain Therapeutics	Head of Medicinal Chemistry
Eli Lilly	Group Leader, Medicinal Chemistry
Eli Lilly	Director Medicinal Chemistry
Eli Lilly and Company	Director External Innovation
F. Hoffmann-La Roche	External collaborations and technologies Manager
Galapagos	Head of Medicinal Chemistry RMV
Galderma	Lead Generation unit Manager
GlaxoSmithKline	Head Discovery Performance Unit
GlaxoSmithKline	Director of Computational Chemistry
Grunenthal	Senior Vice President, Global Drug Development
Janssen	Senior Director of Computational Chemistry
H. Lundbeck A/S	Head of Computational Chemistry
H. Lundbeck A/S	Chief Scientist & Senior Director Medicinal Chemistry
Medivir	Director Chemistry
Merck	Head of Medicinal Chemistry DA
Merck Group	Global Head Discovery Technologies
Merck KGaA	Vice President, Global Head of Medicinal Chemistry
Novartis	Director, Lead Generation Chemistry
Novartis Pharma AG	Executive Director, Drug Discovery
Novartis Pharma AG	Global Head of CPC (Center for Proteomic Chemistry)
Novartis Pharma AG	Head External Science & Drug Discovery, Global Discovery
Orion Corporation	Head of Medicinal Chemistry
Sanofi-Aventis	Head of Medicinal Chemistry, R&D Sanofi Frankfurt
Sanofi-Aventis	Head of Computational Structural Drug Design
Sanofi-Aventis	Global Head, External Innovation and Sourcing
Sanofi-Aventis Deutschland GmbH	Director External Innovation
Takeda	Senior Director of Chemistry
UCB	Director of Chemistry Partnerships
UCB	Director of Medicinal Chemistry
University of Bristol	Professor of Organic Chemistry,
Vernalis Ltd	Research Fellow
Vertex Pharmaceuticals	Head of Crystallography

PAST PARTICIPANTS LIST –EUROPE

Manufacture and Supply Chain

COMPANY	JOB TITLE
Abbott Products Operations	Director of Global Distribution
Astellas	Head of Supply Chain
AstraZeneca	Head of Sourcing & Supply
AstraZeneca	Director Supply Chain Strategy
AstraZeneca	Senior Director, Supply Chain Management
AstraZeneca	Executive Director of Distribution, Global Operations
AstraZeneca	Global Supply Director
AstraZeneca	Executive Director Europe Supply Chain
Baxalta	Global Head Supply Chain, Sourcing & Procurement
Baxter Healthcare	Director Supply Chain Planning & Deployment
Baxter Healthcare	Program Director, Global SC Planning & Deployment
Bio Products Laboratory	Director, Supply Chain and Procurement
Boehringer Ingelheim Ltd	Head of Supply Chain Management
Boehringer Ingelheim Ltd	Corporate Director Supply Chain Integrity
Boehringer Ingelheim Ltd	Director, Head of Network Planning (GPO)
Bristol-Myers Squibb	Director – Supply Planning Centre of Excellence
Bristol-Myers Squibb	Executive Director, Logistics & Global Logistics
Bristol-Myers Squibb	Strategy Integration
Celgene	Associate logistics and Customer service manager
Daiichi Sankyo Development Ltd	Director, Clinical Supplies Operations
Eisai	Director of Clinical Trial Supplies
Eisai Manufacturing Ltd	Senior Director Supply and Demand Management
Ferrer	Head of Corporate Demand Management
GlaxoSmithKline	Head of End to End Logistics Partnership
GlaxoSmithKline	Supply Chain Planning Global Process Lead
GlaxoSmithKline	Supply Chain Logistics Business Partnering
GlaxoSmithKline	Director, Global Supply Chain Strategy & Innovation
IPSEN PHARMA	Vice President Global Supply Chain
IPSEN PHARMA	External Manufacturing
IPSEN PHARMA	Head of Technical & Quality- External Manufacturing
IPSEN PHARMA	Head of External Manufacturing Relationships
Johnson & Johnson	Director, Global Distribution Procurement
Johnson & Johnson Medical Spa	EMEA Operations Process Director
Johnson & Johnson	Senior Manager Global Sourcing
Merck Group	Senior Vice President, Head of Global Supply Network Operations



MERCK

Johnson & Johnson



AstraZeneca



PAST CHINESE SUPPLIERS AND SERVICE PROVIDERS

1. Bioinformatics and Drug Discovery



2. Medicinal Chemistry



3. Manufacture and Supply Chain



SPONSORSHIP PACKAGES

No.	Type	Before 31st July 2018	After 31st July 2018
1	One to One Outsourcing & Partnership meetings	15,000RMB	20,000RMB
Including 2 representatives from vendor company, free participation in Drug Development Summit, 3 (three) pre-selected, pre-qualified one to one meetings. If selected by more buyers from European delegates list, 5000 RMB per extra meeting.			
2	Roundtable Discussion	15,000RMB	20,000RMB
Including 2 representatives from vendor company, free participation in Drug Development Summit, Among 5 sessions under each topic, 2 roundtable meetings will be facilitated by European delegates selected Chinese industry suppliers. Minimum 5 selection to qualify. If selected by more buyers from European delegates list, 5000 RMB per extra meeting.			
3	Mix & Match	25,000RMB	30,000RMB
Including 3 (three) pre-selected, pre-qualified one to one meetings and 1 (one) roundtable discussion.			
4	Drug Development Summit	2,000RMB	2,500RMB
VIP pass to attend Drug Development Summit, discount apply for multiple participants from one organisation.			
5	Exhibition	4,000RMB	5,000RMB
Limited place available, please contact conference organiser for more information			
6	Su Zhou, Jiang Su Networking Tour	2,000RMB	2,500RMB
Including travel, meal and entry tickets. Opportunity for further networking during our one day tour with no restriction.			

For more information, please reach us using contact details below.

CONTACT US

China

Judy Fang 方隽隽

Shanghai BuDou Tech., Ltd.
www.budoutech.com

Phone: 021-59990301
Mobile: 15102198938
QQ: 1991270962

Email: judy.fang@budoutech.com
Address: Room 1103 No. 2500 Zhenbei Road
Shanghai China. 200333

Europe

George Harington

Director, Strategic Partnership

CBMDA Consulting
www.cbmda.org

Phone: +44 (0) 77122 53095

Email: george.harington@cbmda.org
Address: 1 Primrose Street, London, EC2A 2EX



For more information, please scan
and follow us on WeChat

